Omeros EBIT Margin 2010-2024 | OMER
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Omeros (OMER) over the last 10 years. The current EBIT profit margin for Omeros as of December 31, 2024 is .
| Omeros EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2020-06-30 |
$0.07B |
$-0.17B |
-248.53% |
| 2020-03-31 |
$0.08B |
$-0.15B |
-185.19% |
| 2019-09-30 |
$0.10B |
$-0.06B |
-56.44% |
| 2019-06-30 |
$0.08B |
$-0.08B |
-106.58% |
| 2019-03-31 |
$0.05B |
$-0.10B |
-201.96% |
| 2018-12-31 |
$0.03B |
$-0.11B |
-361.29% |
| 2018-09-30 |
$0.02B |
$-0.11B |
-469.57% |
| 2018-06-30 |
$0.04B |
$-0.08B |
-195.00% |
| 2018-03-31 |
$0.06B |
$-0.06B |
-107.27% |
| 2017-12-31 |
$0.07B |
$-0.04B |
-67.69% |
| 2017-09-30 |
$0.06B |
$-0.04B |
-65.63% |
| 2017-06-30 |
$0.05B |
$-0.05B |
-92.45% |
| 2017-03-31 |
$0.05B |
$-0.05B |
-104.35% |
| 2016-12-31 |
$0.04B |
$-0.05B |
-131.71% |
| 2016-09-30 |
$0.04B |
$-0.06B |
-171.43% |
| 2016-06-30 |
$0.03B |
$-0.07B |
-248.15% |
| 2016-03-31 |
$0.02B |
$-0.07B |
-360.00% |
| 2015-12-31 |
$0.01B |
$-0.07B |
-546.15% |
| 2015-09-30 |
$0.01B |
$-0.07B |
-1216.67% |
| 2015-06-30 |
$0.00B |
$-0.07B |
-2366.67% |
| 2015-03-31 |
$0.00B |
$-0.07B |
0.00% |
| 2014-12-31 |
$0.00B |
$-0.07B |
0.00% |
| 2014-09-30 |
$0.00B |
$-0.06B |
0.00% |
| 2014-06-30 |
$0.00B |
$-0.06B |
0.00% |
| 2014-03-31 |
$0.00B |
$-0.06B |
0.00% |
| 2013-12-31 |
$0.00B |
$-0.05B |
-5000.00% |
| 2013-09-30 |
$0.00B |
$-0.04B |
-1466.67% |
| 2013-06-30 |
$0.00B |
$-0.04B |
-1100.00% |
| 2013-03-31 |
$0.01B |
$-0.04B |
-650.00% |
| 2012-12-31 |
$0.01B |
$-0.04B |
-616.67% |
| 2012-09-30 |
$0.01B |
$-0.04B |
-780.00% |
| 2012-06-30 |
$0.01B |
$-0.03B |
-640.00% |
| 2012-03-31 |
$0.00B |
$-0.03B |
-725.00% |
| 2011-12-31 |
$0.00B |
$-0.03B |
-675.00% |
| 2011-09-30 |
$0.00B |
$-0.03B |
-650.00% |
| 2011-06-30 |
$0.00B |
$-0.03B |
-900.00% |
| 2011-03-31 |
$0.00B |
$-0.03B |
-1500.00% |
| 2010-12-31 |
$0.00B |
$-0.03B |
-3000.00% |
| 2010-09-30 |
$0.00B |
$-0.03B |
0.00% |
| 2010-06-30 |
$0.00B |
$-0.02B |
0.00% |
| 2010-03-31 |
$0.00B |
$-0.02B |
0.00% |
| 2009-12-31 |
$0.00B |
$-0.02B |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED PRODUCTS |
$0.409B |
$0.000B |
|
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
|
